Related Experiment Video

Updated: Jun 19, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Optimal antithrombotic treatment in patients with an indication for long-term anticoagulation undergoing coronary

Andrea Rubboli1, Giuseppe Di Pasquale

  • 1Maggiore Hospital, Largo Nigrisoli 2, Division of Cardiology, 40133 Bologna, Italy. andrearubboli@libero.it

Future Cardiology
|October 7, 2009
PubMed

Insights

Optimal antithrombotic therapy remains unknown for patients needing both oral anticoagulation and percutaneous coronary intervention with stent implantation. Current strategies show suboptimal efficacy and safety, necessitating further research.

Area of Science:

  • Cardiology
  • Thrombosis Research
  • Interventional Cardiology

Background:

  • Dual antiplatelet therapy (aspirin and a thienopyridine) is standard after percutaneous coronary intervention with stent implantation (PCI-S).
  • Patients requiring oral anticoagulation (OAC) alongside PCI-S present a complex management challenge due to competing risks of thrombosis and bleeding.
  • Existing evidence on antithrombotic strategies in this population is limited and shows significant variability.

Purpose of the Study:

  • To review the current understanding of optimal antithrombotic treatment in patients undergoing PCI-S who also require long-term OAC.
  • To highlight the challenges and suboptimal outcomes associated with current management strategies.
  • To emphasize the need for further research and risk stratification.

Main Methods:

  • Review of limited available evidence regarding antithrombotic management in patients with combined indications for PCI-S and OAC.
  • Analysis of reported thrombotic and bleeding complication rates with different therapeutic regimens.
  • Discussion of current management strategies including OAC substitution, addition of single antiplatelet, and triple therapy.

Main Results:

  • Current antithrombotic strategies (OAC substitution, addition of single antiplatelet, or triple therapy) demonstrate suboptimal efficacy and safety.
  • A 30-day occurrence of thrombotic complications was reported at 4%, while major bleeding complications ranged from 3-7%.
  • Significant variability exists in clinical practice for managing these high-risk patients.

Conclusions:

  • The optimal antithrombotic treatment for patients undergoing PCI-S with an indication for long-term OAC is currently unknown.
  • Further large-scale registries and clinical trials are essential to establish evidence-based guidelines.
  • Accurate risk stratification for thromboembolic complications is crucial for guiding periprocedural and long-term management in the interim.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...